Remedee Labs

Remedee Labs operates at the intersection of medical devices, digital health, and chronic-pain care. Its main distinction is a drug-free, wearable approach: millimeter-wave neuromodulation delivered through a wristband, paired with a digital support platform. The company identifies fibromyalgia and osteoarthritis as target conditions through Fibro Rem™ and Novi Rem™; its European approval for fibromyalgia therapy, announced in September 2024, is a concrete regulatory milestone. Its model combines a physical medical device with patient support and monitoring rather than relying on a standalone consumer wellness app. The competitive context is therefore best understood as a developing segment spanning established pain therapies, medical-device interventions, and digital care programs. Remedee’s differentiators are its millimeter-wave method, wearable format, stated clinical-research foundation, and focus on chronic-pain conditions. With 11–50 employees and approximately $24.8 million in recorded funding, it remains a relatively small private company compared with established medical-device groups, while its regulatory and clinical progress provides a more relevant basis for assessing its position than scale alone.

Remedee Labs’ development reflects a progression from research-led device creation toward a combined therapy and digital-care offering. Founded in 2016, the company’s early financing included a $12 million Series A on Nov 14, 2019. A second Series A, announced on Dec 6, 2022, added €12.2 million, or $12,770,189, bringing structured recorded funding to $24,770,189. These financings supported a portfolio that now includes Fibro Rem™ for fibromyalgia, Novi Rem™ for osteoarthritis, a wearable endorphin-stimulating wristband, and the my Remedee™ digital support platform. A notable leadership inflection point came in May 2021, when Gilles Litman, formerly a digital health vice president at Sanofi, joined the company to support international launch efforts. The September 2024 European approval for its fibromyalgia wristband therapy marked a further shift from product development toward regulated-market adoption. The available employee indicator places the company in the 11–50 range, but no hiring trend or later financing is reported. Its next growth phase therefore appears to depend on translating regulatory progress and its device-plus-platform model into sustained patient and market adoption; current information does not establish the scale of that adoption.